Teva Pharmaceutical Industries

• A New Drug Sales Model

  By Reuben Brewer - May 20, 2013 | Tickers: NVO, PFE, TEVA |

  Pfizer (NYSE: PFE) is trying a new sales paradigm, selling direct to patients. If this effort works, it could completely change the pharmaceutical industry.

  Little blue pills

  One of Pfizer's best selling drugs is Viagra, which is used to treat erectile dysfunction. That particular ailment carries material social stigma and the pills, which are still under patent protection for many more years, can be expensive. That has proven to more »

• Good News For Health Care Stocks Part 2

  By Reuben Brewer - May 17, 2013 | Tickers: JNJ, PRGO, TEVA

  It isn't surprising that providing Medicaid coverage to lower-income residents of Oregon led to an increased use of health care services. However, taking that finding a step further can lead to some interesting investing ideas.

  The Oregon Study

  The New England Journal of Medicine recently released the results of the Oregon Study. That research tracked Oregon's test of randomly assigning lower-income adults into a group that received Medicaid more »

• 4 Big Drug Companies With Big Juicy Yields

  By David Dierking - May 16, 2013 | Tickers: LLY, MRK, PFE, TEVA

  Drug companies have long had the ability to be revenue generating machines. They’re in the enviable position of being able to profit from the aging of America by providing a product that will be in continuous demand. While those revenue streams can hit some peaks and valleys due to things like drug patent expiration (something that Pfizer (PFE) will be dealing with shortly with its big name drug Lipitor more »

• Following Up an Acquisition With an Even Larger Merger?

  By Mike Thiessen - May 15, 2013 | Tickers: ACT, TEVA, VRX

  News that Montreal-based Valeant Pharmaceuticals (NYSE: VRX) was in talks to merge with Parsippany, New Jersey-based Actavis (NYSE: ACT) emerged barely a week after the completion of the company's tender offer for Obagi Pharmaceuticals (OMPI). Although the deal remains in its early stages and has been the subject of wild and conflicting rumors, it could prove to be one of the largest pharmaceutical mergers in recent years. Its current more »

• I Would Buy a Generic Drug ETF, If One Existed

  By Seth Robey - May 2, 2013 | Tickers: BBH, IBB, NVS, XBI, TEVA |

  About 120 drugs have lost or will lose patent protection in 2013.  EvaluatePharma estimates that this accounts for nearly $29 billion in total annual revenue, a number which will grow ten-fold between now and 2018.  As big biotech and big pharma dive head-first off the patent cliff, there is suddenly an expanding market for cheap generic versions of blockbuster drugs of the past.  Investors looking to profit from growing sales more »

• Which One Should Investors Buy: The Ex-Parent or the Spin-off?

  By Anh HOANG - April 24, 2013 | Tickers: ABT, ABBV, TEVA

  Tom Russo, a partner at Gardner Russo & Gardner, has managed to deliver a 13.2% annualized return for the past 25 years, beating the S&P 500’s annualized return of 9.7%. As of March 2013, he had more than $8.5 billion in total assets under management with around 255 stocks in his portfolio.

  In the first quarter of 2013, he purchased 88,250 shares in AbbVie (NYSE: ABBVmore »)

• Does Teva Have a Silver Lining?

  By Lior Cohen - April 22, 2013 | Tickers: IPXL, MRK, PFE, TEVA

  The weakness of Teva Pharmaceutical Industries (NYSE: TEVA) in the stock market is keeping away investors from this generic drug manufacturing giant. Next month the company will publish its financial reports for the first quarter of 2013. Will this company’s financial reports help rally its stock? Does the company have a silver lining that might pull shares of the company up in 2013?

  First, let’s examine the company more »

• Teva Pharmaceuticals: Will the Transition Be Effective?

  By Shas Dey - April 22, 2013 | Tickers: ACT, MYL, TEVA |

  Teva (NYSE: TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting example of a company in transition. Investors are currently not well-favored towards Teva given the uncertainty looming over its drug pipeline and the consequences of the new strategy being implemented by its newly appointed CEO, but there is merit in the changes being carried out at this firm.

  Copaxone patent more »

• Will Dividend Growth for This Dividend King Start Slowing?

  By Michael Weber - April 18, 2013 | Tickers: BAX, CAH, JNJ, TEVA

  Johnson & Johnson (NYSE: JNJ) has been considered a dividend growth star for a number of years now. They have increased their dividend for 50 consecutive years and currently sport an impressive 5 and 10 year dividend growth rate of 8.2% and 11.6%. 

  With these types of dividend growth rates and such a long dividend streak it is easy to see why Johnson & Johnson is considered a favorite among more »

• A Few Reasons Why You Should Stay Away From This Pharma Company

  By Wes Patoka - April 17, 2013 | Tickers: JNJ, PFE, TEVA

  Teva Pharmaceutical (NYSE: TEVA) is the world’s largest generic drug manufacturer, and it may sound like a bargain at $40 and with a PE of 17.5. However, Hewlett-Packard sounded like a bargain at $30 in the beginning of 2012, before it dropped another $10 to around $20 today.

  The reason for the comparison between Teva and HP is because both of them are in industries experiencing commoditization, the more »

• Teva Pharmaceuticals – will the transition be effective?

  By Shas Dey - April 16, 2013 | Tickers: ACT, MYL, TEVA

  Teva (NYSE: TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting example of a company in transition. Investors are currently not well-favored towards Teva given the uncertainty looming over its drug pipeline and the consequences of the new strategy being implemented by its newly appointed CEO, but there is merit in the changes being carried out at this firm.

  Copaxone patent more »

• Investing in Pharmaceuticals? Ask Phillip Frost

  By Anh HOANG - April 15, 2013 | Tickers: BMY, OPK, TEVA

  Insiders always know about their company much better than retail investors do. That's why it is wise for us to watch recent insider trading activity closely besides the company’s fundamentals. Since the beginning of April, Dr. Phillip Frost, CEO and Chairman of Opko Health (NYSE: OPK), has accumulated nearly 570,000 shares of the company at a total transaction value of more than $4 million.

  Interestingly, Dr. Frost more »

• Teva Pharmaceuticals: Stay away by doctors orders.

  By Wes Patoka - April 13, 2013 | Tickers: JNJ, PFE, TEVA

  Teva pharmaceutical (NYSE: TEVA) is the world’s largest generic drug manufacturer, and it may sound like a bargain at $40 and with a PE of 17.5. However, Hewlett Packard sounded like a bargain at $30 in the beginning of 2012, before it dropped another $10 to around $20 today. The reason for the comparison between Teva and HP is because both of them are in industries experiencing commoditization more »

• Landmark Judgment Could Give These Stocks a Boost

  By Jacob Wolinsky - April 12, 2013 | Tickers: ACT, PRGO, TEVA

  A federal judge in Brooklyn, New York, has ruled that the morning-after pill (levonorgestrel) used as an emergency contraceptive will now be available over the counter with no age restrictions.

  Judge Edward Korman’s ruling effectively overturned a previous decision by the Secretary of Health and Human Services, as it was considered to be "arbitrary, capricious, and unreasonable" by Korman. The previous decision urged the FDA to reject a petition more »

• This Pharma Company Needs to Take Urgent Measures

  By Mohsin Saeed - April 8, 2013 | Tickers: AZN, PFE, TEVA

  A number of large pharmaceutical companies are currently undergoing a patent crisis. A large number of  star drugs are facing expiring patents, putting a lot of strain on FDA to increase their approval rate.

  AstraZeneca (NYSE: AZN) is one of the most affected companies when it comes to a diminishing patent portfolio. The company is facing a major generic threat to some of its key drugs. It's leading drugs more »

• A Bidding War in Skin Care

  By Robert Hanley - April 6, 2013 | Tickers: OMPI, TEVA, VRX

  Serial acquirer Valeant Pharmaceuticals (NYSE: VRX) thought it had locked up an acquisition of Obagi Medical Products (NASDAQ: OMPI) in late March for $19 per share in cash or roughly $344 million. The purchase would have added leading skin treatment products to the company’s growing dermatology franchise. On April 2^nd, though, Germany-based Merz Pharma made a higher, competing offer for Obagi, which led to a counter offer from more »

• AstraZeneca: More Urgent Measures are Needed

  By Mohsin Saeed - April 4, 2013 | Tickers: AZN, PFE, TEVA

  A number of large-pharmaceutical companies are currently undergoing a patent crisis. As a large number of  star drugs are facing expiring patent which has put a lot of strain on FDA to increase their approval rate. AstraZeneca (NYSE: AZN) is one of the most affected companies when it comes to diminishing patent portfolio. The company is facing a major generic threat to some of its key drugs. It's leading more »

• Hmm….This Bostonian Hedge Fund Is Bullish Alright

  By Meena Krishnamsetty - April 3, 2013 | Tickers: LAMR, NXY, SLM, TEVA, WAIR

  Abrams Capital Management is one of the largest hedge funds in Boston. The fund is run by David Abrams, and has a $5 million minimum requirement. Currently valued as an equity portfolio alone worth $1.1 billion, Abrams’ investment vehicle primarily invests in financial, services and basic materials stocks and tends to favor securities that are undervalued. In accordance with our market-beating strategy, we’re going to take a look more »

• This Hedge Fund Knows Heathcare, Do You?

  By Meena Krishnamsetty - March 28, 2013 | Tickers: ALKS, ANGO, BABY, SNTS, TEVA

  Healthcare stocks aren’t for everyone, but one way average investors can learn more about this space is by paying attention to those who make a career out of it. Kevin Kotler's Broadfin Capital is entirely invested in healthcare stocks and represents a good piggybacking candidate, so to speak. Interestingly, his top five positions make up roughly one-third of his $404 million equity portfolio, according to his latest 13F more »

• Get the Best of Both Worlds With This Pharmaceutical Company

  By Greg Williamson - March 25, 2013 | Tickers: CELG, LLY, TEVA

  The pharmaceutical industry has two very distinct product options: branded drugs and generics. Advancing a branded product from the initial discovery to successful commercialization requires extensive research, trials, and marketing efforts that can take many years and millions of dollars. Sometimes these efforts result in failure when adverse effects occur or the appropriate approvals are not obtained. However, a company and its investors can be rewarded substantially with Billions in more »

• Page 1 of 5
• »